001377147 000__ 02469cam\\2200481\i\4500
001377147 001__ 1377147
001377147 003__ OCoLC
001377147 005__ 20211015003131.0
001377147 007__ he\bmb024bbca
001377147 008__ 210305s2019\\\\dcu\\\\\b\\\\f000\0\eng\d
001377147 0248_ $$a38-320$$q(GPO jacket number)
001377147 035__ $$a(OCoLC)1240504377
001377147 040__ $$aGPO$$beng$$erda$$cGPO$$dOCLCO$$dOCLCF$$dISE
001377147 043__ $$an-us---
001377147 049__ $$aISEA
001377147 074__ $$a1016-B (MF)
001377147 0860_ $$aY 4.OV 2:116-55
001377147 088__ $$aSerial no. 116-55 (United States. Congress. House. Committee on Oversight and Reform)
001377147 1101_ $$aUnited States.$$bCongress.$$bHouse.$$bCommittee on Oversight and Reform,$$eauthor.
001377147 24514 $$aThe patient perspective :$$bthe devastating impacts of skyrocketing drug prices on American families : hearing before the Committee on Oversight and Reform, House of Representatives, One Hundred Sixteenth Congress, first session, July 26, 2019.
001377147 24630 $$aDevastating impacts of skyrocketing drug prices on American families
001377147 264_1 $$aWashington :$$bU.S. Government Publishing Office,$$c2019.
001377147 300__ $$aiii, 41 pages ;$$c24 cm
001377147 336__ $$atext$$btxt$$2rdacontent
001377147 337__ $$amicroform$$bh$$2rdamedia
001377147 338__ $$amicrofiche$$bhe$$2rdacarrier
001377147 500__ $$a"Serial no. 116-55."
001377147 500__ $$aShipping list no.: 2021-0040-M.
001377147 5110_ $$aHearing witnesses: David Mitchell, Patient, Founder- Patients for Affordable Drugs, Bethesda, MD; Ashley Krege, Patient, Houston, Texas; Laura McLinn, Mother of Patient (Minority Witness), Indianapolis, Indiana; Sa'Ra Skipper, Patient, Indianapolis, Indiana; Pam Holt, Patient, Grangier, Indiana.
001377147 518__ $$aDate of hearing: 2019-07-26.
001377147 533__ $$aMicrofiche.$$b[Washington, D.C.] :$$cU.S. Government Printing Office,$$d[2020]$$e1 microfiche : negative.
001377147 650_0 $$aDrugs$$xPrices$$xHealth aspects$$zUnited States.
001377147 650_0 $$aPrescription pricing$$xGovernment policy$$zUnited States.
001377147 650_0 $$aPharmaceutical industry$$xGovernment policy$$zUnited States.
001377147 650_7 $$aPharmaceutical industry$$xGovernment policy.$$2fast$$0(OCoLC)fst01060149
001377147 650_7 $$aPrescription pricing$$xGovernment policy.$$2fast$$0(OCoLC)fst01075658
001377147 651_7 $$aUnited States.$$2fast$$0(OCoLC)fst01204155
001377147 655_7 $$aLegislative hearings.$$2fast$$0(OCoLC)fst01910825
001377147 655_7 $$aLegislative hearings.$$2lcgft
001377147 77608 $$iPrint version:$$aUnited States. Congress. House. Committee on Oversight and Reform.$$tPatient perspective$$w(DLC)  2019394684$$w(OCoLC)1131722250
001377147 77608 $$iOnline version:$$aUnited States. Congress. House. Committee on Oversight and Reform.$$tPatient perspective$$w(OCoLC)1130761617
001377147 852__ $$bdfich
001377147 852__ $$bedoc$$hY 4.OV 2:116-55
001377147 85640 $$uhttps://purl.fdlp.gov/GPO/gpo129704
001377147 909CO $$ooai:library.usi.edu:1377147$$pGLOBAL_SET
001377147 980__ $$aBIB
001377147 980__ $$aEGOV
001377147 982__ $$aGovernment E-Resource
001377147 983__ $$aOnline
001377147 994__ $$aC0$$bISE